公开(公告)号：US20220220220A1

公开(公告)日：2022-07-14

申请号：US17570649

申请日：2022-01-07

Applicant: Bristol-Myers Squibb Company ,  Janssen Pharmaceuticals, Inc.

Inventor： Joseph M. Luettgen ,  Lumelle Schneeweis ,  Ginger Chao Rakestraw ,  Christina Terragni ,  Andrew Karl Dilger ,  Jason Robert Pinckney ,  Steven Sheriff ,  Kevin Kish ,  Yongmi An ,  William R. Ewing ,  Stanley Richard Krystek, JR. ,  Aaron Paul Yamniuk

IPC: C07K16/36 ,  C07K16/44 ,  A61P7/04 ,  G01N33/86 ,  G01N33/94

Abstract: The present invention provides novel antigen binding peptides, such as an antibody or antibody fragment, that specifically bind to selective FXIa inhibitors and/or dual inhibitors of FXIa, and plasma kallikrein. The present invention further relates to methods of reducing the antithrombotic effect of FXIa inhibitors by administering to a subject a pharmaceutically effective dose of the antigen binding peptides provided herein. In addition, the present invention provides detection reagents and methods for detecting the level of the inhibitors of FXIa in a biological sample.

公开(公告)号：US10584160B2

公开(公告)日：2020-03-10

申请号：US15760449

申请日：2016-09-22

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Dasa Lipovsek ,  Joseph Toth ,  Ginger C. Rakestraw ,  Irvith M. Carvajal ,  Stanley Richard Krystek, Jr. ,  Steven R. O'Neil ,  Guodong Chen ,  Richard Y. Huang ,  Bryan C. Barnhart ,  John Thomas Loffredo ,  Christina Terragni

IPC: C07K14/78 ,  A61K47/64 ,  G01N33/68 ,  A61K38/00

Abstract: Provided herein are polypeptides which include tenth fibronectin type III domains (10Fn3) that bind to glypican-3. Also provided are fusion molecules comprising a 10Fn3 domain that bind to glypican-3 for use in diagnostic and therapeutic applications. Glypican-3 10Fn3 drug conjugates are also provided.

公开(公告)号：US12065505B2

公开(公告)日：2024-08-20

申请号：US17570649

申请日：2022-01-07

Applicant: Bristol-Myers Squibb Company ,  Janssen Pharmaceuticals, Inc.

Inventor： Joseph M. Luettgen ,  Lumelle Schneeweis ,  Ginger Chao Rakestraw ,  Christina Terragni ,  Andrew Karl Dilger ,  Jason Robert Pinckney ,  Steven Sheriff ,  Kevin Kish ,  Yongmi An ,  William R. Ewing ,  Stanley Richard Krystek, Jr. ,  Aaron Paul Yamniuk

IPC: C07K16/36 ,  A61K39/00 ,  A61P7/04 ,  C07K16/44 ,  G01N33/86 ,  G01N33/94

CPC classification number: C07K16/36 ,  A61P7/04 ,  C07K16/44 ,  G01N33/86 ,  G01N33/94 ,  A61K2039/505 ,  C07K2317/21 ,  C07K2317/55 ,  C07K2317/565 ,  C07K2317/92

Abstract: The present invention provides novel antigen binding peptides, such as an antibody or antibody fragment, that specifically bind to selective FXIa inhibitors and/or dual inhibitors of FXIa, and plasma kallikrein. The present invention further relates to methods of reducing the antithrombotic effect of FXIa inhibitors by administering to a subject a pharmaceutically effective dose of the antigen binding peptides provided herein. In addition, the present invention provides detection reagents and methods for detecting the level of the inhibitors of FXIa in a biological sample.

公开(公告)号：US11524992B2

公开(公告)日：2022-12-13

申请号：US16751788

申请日：2020-01-24

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Dasa Lipovsek ,  Joseph Toth ,  Ginger C. Rakestraw ,  Irvith M. Carvajal ,  Stanley Richard Krystek, Jr. ,  Steven R. O'Neil ,  Guodong Chen ,  Richard Y. Huang ,  Bryan C. Barnhart ,  John Thomas Loffredo ,  Christina Terragni

IPC: C07K14/78 ,  A61K47/64 ,  G01N33/68 ,  A61K38/00 ,  A61K47/60

Abstract: Provided herein are polypeptides which include tenth fibronectin type III domains (10Fn3) that bind to glypican-3. Also provided are fusion molecules comprising a 10Fn3 domain that bind to glypican-3 for use in diagnostic and therapeutic applications. Glypican-3 10Fn3 drug conjugates are also provided.